These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 35349743)

  • 1. Safety of ustekinumab in adolescent patients with moderate-to-severe plaque psoriasis: real-world evidence from an ongoing European study (NCT03218488).
    Mahé E; Geldhof A; Jazra M; Bergmans P; Azzabi A; Seyger MMB
    J Eur Acad Dermatol Venereol; 2022 Aug; 36(8):e646-e648. PubMed ID: 35349743
    [No Abstract]   [Full Text] [Related]  

  • 2. Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis.
    Fioranelli M; Roccia MG; Lotti T
    Dermatol Ther; 2017 Sep; 30(5):. PubMed ID: 28508536
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparative 12-week effectiveness and safety outcomes of biologic agents ustekinumab, secukinumab and ixekizumab for the treatment of plaque psoriasis: a real-world multicenter retrospective study.
    Georgakopoulos JR; Lam K; Sandhu VK; Ighani A; Phung M; Piguet V; Yeung J
    J Eur Acad Dermatol Venereol; 2020 Aug; 34(8):e416-e418. PubMed ID: 32176394
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
    Gordon KB; Strober B; Lebwohl M; Augustin M; Blauvelt A; Poulin Y; Papp KA; Sofen H; Puig L; Foley P; Ohtsuki M; Flack M; Geng Z; Gu Y; Valdes JM; Thompson EHZ; Bachelez H
    Lancet; 2018 Aug; 392(10148):650-661. PubMed ID: 30097359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An analysis of Drug Survival, Effectiveness, and Safety in Moderate to Severe Psoriasis Treated With Ustekinumab: An Observational Study of 69 Patients in Routine Clinical Practice.
    Salgüero Fernández I; Gil MH; Sanz MS; Gullón GR
    Actas Dermosifiliogr (Engl Ed); 2019 Apr; 110(3):244-246. PubMed ID: 29961546
    [No Abstract]   [Full Text] [Related]  

  • 6. Ixekizumab vs ustekinumab for skin clearance in patients with moderate to severe psoriasis after a year of treatment: Real-world practice.
    Herrera-Acosta E; Garriga-Martina GG; Suárez-Pérez JA; Martínez-García E; Herrera-Ceballos E
    Dermatol Ther; 2020 Nov; 33(6):e14202. PubMed ID: 32808703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study.
    Blauvelt A; Reich K; Tsai TF; Tyring S; Vanaclocha F; Kingo K; Ziv M; Pinter A; Vender R; Hugot S; You R; Milutinovic M; Thaçi D
    J Am Acad Dermatol; 2017 Jan; 76(1):60-69.e9. PubMed ID: 27663079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrated safety analysis of treatment-emergent eczematous reactions in patients with moderate-to-severe psoriasis treated with ixekizumab, etanercept and ustekinumab.
    Brunner PM; Conrad C; Vender R; Grond S; Schuster C; Patel H; Xu W; Carrascosa Carrillo JM
    Br J Dermatol; 2021 Oct; 185(4):865-867. PubMed ID: 34076896
    [No Abstract]   [Full Text] [Related]  

  • 9. Secukinumab demonstrates superior efficacy and a faster response in clearing skin in Asian subjects with moderate to severe plaque psoriasis compared with ustekinumab: Subgroup analysis from the CLEAR study.
    Lee MG; Huang YH; Lee JH; Lee SC; Kim TG; Aw DC; Bao W; Dee CMA; Guana A; Tsai TF
    J Dermatol; 2019 Sep; 46(9):752-758. PubMed ID: 31342560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Severe disseminated Nocardia infection associated with ustekinumab treatment for psoriasis.
    Couture-Cossette A; Morand M; Vinh DC; Gratton M; Martin P
    Br J Dermatol; 2019 Jul; 181(1):194-195. PubMed ID: 30657168
    [No Abstract]   [Full Text] [Related]  

  • 11. Case of recurrent severe cellulitis and cutaneous candidiasis during psoriasis treatment with ustekinumab.
    Miyachi H; Nakamura Y; Wakabayashi S; Iwasawa MT; Oikawa A; Watanabe A; Matsue H
    J Dermatol; 2017 Aug; 44(8):e206-e207. PubMed ID: 28432713
    [No Abstract]   [Full Text] [Related]  

  • 12. Safety of ustekinumab in severe psoriasis with chronic hepatitis B.
    Raymundo AR; Facin AP; Silva de Castro CC; Faria AR
    Indian J Dermatol Venereol Leprol; 2016; 82(3):326-8. PubMed ID: 27088944
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficacy and safety of ustekinumab in a group of 22 elderly patients with psoriasis over a 2-year period.
    Megna M; Napolitano M; Balato N; Monfrecola G; Villani A; Ayala F; Balato A
    Clin Exp Dermatol; 2016 Jul; 41(5):564-6. PubMed ID: 27028505
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy and Safety of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis and Skin of Color: Results from the Pooled AMAGINE-2/-3 Randomized Trials.
    McMichael A; Desai SR; Qureshi A; Rastogi S; Alexis AF
    Am J Clin Dermatol; 2019 Apr; 20(2):267-276. PubMed ID: 30471012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ustekinumab for the treatment of psoriasis: an evidence update.
    Yiu ZZ; Warren RB
    Semin Cutan Med Surg; 2018 Sep; 37(3):143-147. PubMed ID: 30215630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risankizumab vs. ustekinumab for plaque psoriasis: a critical appraisal.
    Al-Janabi A; Jabbar-Lopez ZK; Griffiths CEM; Yiu ZZN
    Br J Dermatol; 2019 Jun; 180(6):1348-1351. PubMed ID: 30632140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biological treatments for paediatric psoriasis : a retrospective observational study on biological drug survival in daily practice in childhood psoriasis.
    Phan C; Beauchet A; Burztejn AC; Severino-Freire M; Barbarot S; Girard C; Lasek A; Reguiai Z; Hadj-Rabia S; Abasq C; Brenaut E; Droitcourt C; Perrussel M; Mallet S; Phan A; Lacour JP; Khemis A; Bourrat E; Chaby G; Deborde R; Plantin P; Maruani A; Piram M; Maccari F; Fougerousse AC; Kupfer-Bessaguet I; Balguérie X; Barthelemy H; Martin L; Quiles-Tsimaratos N; Mery-Brossard L; Pallure V; Lons-Danic D; Bouilly-Auvray D; Beylot-Barry M; Puzenat E; Aubin F; Mahé E; ;
    J Eur Acad Dermatol Venereol; 2019 Oct; 33(10):1984-1992. PubMed ID: 30883928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ustekinumab treatment for moderate to severe psoriasis. Eight-year real-world follow-up of 61 cases in a tertiary level hospital.
    Elberdín L; Fernández-Torres R; Paradela S; Blanco E; Outeda M; Martín I; Fonseca E
    J Dermatolog Treat; 2020 Nov; 31(7):698-701. PubMed ID: 30961404
    [No Abstract]   [Full Text] [Related]  

  • 19. Exacerbation of infliximab-induced paradoxical psoriasis after ustekinumab therapy.
    Suh HY; Ahn JY; Park MY; Youn JI
    J Dermatol; 2018 Mar; 45(3):332-333. PubMed ID: 28295521
    [No Abstract]   [Full Text] [Related]  

  • 20. Real-world efficacy of biological agents in moderate-to-severe plaque psoriasis: An analysis of 75 patients in Taiwan.
    Chen YC; Huang YT; Yang CC; Lai EC; Liu CH; Hsu CK; Wong TW; Chao SC; Sheu HM; Lee CN
    PLoS One; 2020; 15(12):e0244620. PubMed ID: 33373425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.